Anti ‐PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care

ConclusionsAnti‐PCSK9 antibodies effectively lower LDL‐C levels in a broad patient population. While awaiting comprehensive data from CV outcome trials, these agents should be considered in very high risk patients, such as those in secondary prevention and those with familial hypercholesterolaemia who are already receiving maximally tolerated LLTs, have not achieved their LDL‐C goal and require substantial reductions in LDL‐C.

Source: International Journal of Clinical Practice - July 1, 2017 Category: Internal Medicine Authors: Olivier S. Descamps, Uwe Fraass, Ricardo Dent, Winfried M ärz, Ioanna Gouni‐Berthold Tags: REVIEW ARTICLE Source Type: research